TNF Pharmaceuticals (TNFA) Competitors

In the previous week, Tevogen Bio had 1 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 1 mentions for Tevogen Bio and 0 mentions for TNF Pharmaceuticals. Tevogen Bio's average media sentiment score of 0.00 equaled TNF Pharmaceuticals'average media sentiment score.

Tevogen Bio presently has a consensus price target of $100.00, suggesting a potential upside of 1,256.85%. Given Tevogen Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Tevogen Bio is more favorable than TNF Pharmaceuticals.

Tevogen Bio is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

9.6% of TNF Pharmaceuticals shares are held by institutional investors. 70.5% of Tevogen Bio shares are held by insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tevogen Bio has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500.

Tevogen Bio's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

In the previous week, Celularity had 2 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 2 mentions for Celularity and 0 mentions for TNF Pharmaceuticals. Celularity's average media sentiment score of 0.20 beat TNF Pharmaceuticals' score of 0.00 indicating that Celularity is being referred to more favorably in the media.

19.0% of Celularity shares are held by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TNF Pharmaceuticals has lower revenue, but higher earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Celularity presently has a consensus target price of $6.00, suggesting a potential upside of 529.66%. Given Celularity's stronger consensus rating and higher possible upside, research analysts plainly believe Celularity is more favorable than TNF Pharmaceuticals.

TNF Pharmaceuticals has a net margin of 0.00% compared to Celularity's net margin of -198.75%. Celularity's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

Celularity has a beta of 0.44, meaning that its stock price is 56% less volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500.

TNF Pharmaceuticals' return on equity of -69.21% beat Tvardi Therapeutics' return on equity.

9.6% of TNF Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 0.5% of TNF Pharmaceuticals shares are owned by insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

TNF Pharmaceuticals has a beta of 2.04, suggesting that its stock price is 104% more volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

In the previous week, TNF Pharmaceuticals' average media sentiment score of 0.00 equaled Tvardi Therapeutics'average media sentiment score.

Tvardi Therapeutics has a consensus price target of $55.50, indicating a potential upside of 1,404.07%. Given Tvardi Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Tvardi Therapeutics is more favorable than TNF Pharmaceuticals.

Tvardi Therapeutics has higher revenue and earnings than TNF Pharmaceuticals. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than TNF Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Kyntra Bio has a net margin of 2,848.19% compared to TNF Pharmaceuticals' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat TNF Pharmaceuticals' return on equity.

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 9.6% of TNF Pharmaceuticals shares are held by institutional investors. 2.0% of Kyntra Bio shares are held by company insiders. Comparatively, 0.5% of TNF Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Kyntra Bio has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, TNF Pharmaceuticals has a beta of 2.04, indicating that its share price is 104% more volatile than the S&P 500.

In the previous week, Kyntra Bio had 2 more articles in the media than TNF Pharmaceuticals. MarketBeat recorded 2 mentions for Kyntra Bio and 0 mentions for TNF Pharmaceuticals. Kyntra Bio's average media sentiment score of 0.00 equaled TNF Pharmaceuticals'average media sentiment score.

Kyntra Bio has higher revenue and earnings than TNF Pharmaceuticals. TNF Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.